



Early View

Original research article

Predicting the risk of respiratory distress in newborns with congenital pulmonary malformations

Christophe Delacourt, Laurent J. Salomon, Makan Rashenas, Alexandra Benachi, Arnaud Bonnard, Laure Choupeaux, Virginie Fouquet, Valérie Goua, Frédéric Hameury, Erik Hervieux, Jean-Marie Jouannic, Naziha Khen-Dunlop, Gwenaelle Le Bouar, Jérôme Massardier, Léa Roditis, Jonathan Rosenblatt, Agnès Sartor, Catherine Thong-Vanh, Nathalie Lelong, Babak Khoshnood, for the MALFPULM study group

Please cite this article as: Delacourt C, Salomon LJ, Rashenas M, *et al.* Predicting the risk of respiratory distress in newborns with congenital pulmonary malformations. *Eur Respir J* 2021; in press (<https://doi.org/10.1183/13993003.00949-2021>).

This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Predicting the risk of respiratory distress in newborns with congenital pulmonary malformations

Christophe DELACOURT, MD, PhD^{1,2}, Nathalie BERTILLE, PhD³, Laurent J. SALOMON, MD, PhD^{2,4}, Makan RASHENAS, MD, MPH³, Alexandra BENACHI, MD, PhD⁵, Arnaud BONNARD, MD, PhD⁶, Laure CHOUPEAUX, MSc⁷, Virginie FOUQUET, MD⁸, Valérie GOUA, MD⁹, Frédéric HAMEURY, MD¹⁰, Erik HERVIEUX, MD¹¹, Jean-Marie JOUANNIC, MD, PhD¹², Naziha KHEN-DUNLOP, MD, PhD¹³, Gwenaëlle LE BOUAR, MD¹⁴, Jérôme MASSARDIER, MD, PhD¹⁵, Léa RODITIS, MD¹⁶, Jonathan ROSENBLATT, MD, PhD¹⁷, Agnès SARTOR, MD¹⁸, Catherine THONG-VANH, MD¹⁹, Nathalie LELONG, MSc³, Babak KHOSHNOOD, MD, PhD³, for the MALFPULM study group*

¹ AP-HP, Hôpital Necker-Enfants Malades, Service de Pneumologie et Allergologie Pédiatriques, Paris, France

² Université de Paris, Paris, France

³ Inserm UMR 1153, Maternité Port-Royal, Paris, France

⁴ AP-HP, Hôpital Necker-Enfants Malades, Service d'Obstétrique, Paris, France

⁵ AP-HP, Hôpital Antoine Bécclère, Service de Gynécologie-Obstétrique, Université Paris Sud, Clamart, France.

⁶ AP-HP, Hôpital Robert Debré, Service de Chirurgie Pédiatrique, Paris, France

⁷ AP-HP, Unité de Recherche Clinique Cochin-Necker, Paris, France

⁸ AP-HP, Hôpital Bicêtre, Service de Chirurgie Pédiatrique, Paris, France

⁹ Service d'Obstétrique, CHU Poitiers, France

¹⁰ Hospices Civils de Lyon, HFME, Service de Chirurgie Pédiatrique, Lyon, France

¹¹ AP-HP, Hôpital Armand-Trousseau, Service de Chirurgie Pédiatrique, Paris, France

¹² AP-HP, Hôpital Armand-Trousseau, Service de Gynécologie-Obstétrique, Université Paris Sud, Clamart, France

¹³ AP-HP, Hôpital Necker-Enfants Malades, Service de Chirurgie Pédiatrique, Paris, France

¹⁴ Service d'Obstétrique, CHU Rennes, France

¹⁵ Hospices Civils de Lyon, HFME, Service d'Obstétrique, France

¹⁶ Service de Pneumologie Pédiatrique, CHU Toulouse, France

¹⁷ AP-HP, Hôpital Robert Debré, Service d'Obstétrique, Paris, France

¹⁸ Service d'Obstétrique, CHU Toulouse, France

¹⁹ Service d'Obstétrique, CHU Grenoble, France

* A complete list of the MALFPULM study group members can be found in the Acknowledgments

Corresponding Author: Christophe Delacourt
Service de Pneumologie et Allergologie Pédiatrique
Hôpital Necker-Enfants Malades
149-161 rue de Sèvres, 75015 Paris, France
Tel. + 33 1 44 49 48 38 Fax. + 33 1 44 38 17 40
E-mail christophe.delacourt@aphp.fr

TAKE HOME MESSAGE

First large prospective population-based cohort of children with prenatally diagnosed congenital pulmonary malformations identified CVR as the best predictive marker of neonatal respiratory distress, helping to guide the delivery site.

Conflict of Interest Disclosures: The authors have no conflicts of interest relevant to this article to disclose

Funding: The MALFPULM study was sponsored by the *Assistance Publique-Hôpitaux de Paris (Département de la Recherche Clinique et du Développement)*. The study was funded by a grant from the *Programme Hospitalier de Recherche Clinique – PHRC 2013 (Ministère de la Santé, No.AOM130581 – NI13005)*.

Role of Funder: The funder did not participate in the work

ClinicalTrials.gov Identifier: NCT02352207

Abbreviations

CPM: Congenital Pulmonary Malformation

CVR: Congenital Pulmonary Malformation Volume Ratio

NRD: Neonatal Respiratory Distress

Contributors' Statement Page

Profs Delacourt, and Koshnood conceptualized and designed the study, supervised analysis, drafted the initial manuscript, and reviewed and revised the manuscript.

Drs Bertille, Mrs Choupeaux and Lelong designed the data collection instruments, collected data, carried out the initial analyses, and reviewed and revised the manuscript.

Dr Rashenas carried out the analyses, and reviewed and revised the manuscript.

Profs Salomon, and Benachi, conceptualized and designed the study, coordinated and supervised data collection, and critically reviewed the manuscript for important intellectual content.

Prof Bonnard, Jouannic, Massardier, Drs Fouquet, Goua, Hameury, Hervieux, Khen-dunlop, Le Bouar, Roditis, Rosenblatt, Sartor, and Thong-vanh coordinated and supervised data collection, contributed to interpretation of data, and critically reviewed the manuscript for important intellectual content.

All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

ABSTRACT

Objectives: Most children with prenatally diagnosed congenital pulmonary malformations (CPM) are asymptomatic at birth. We aimed to develop a parsimonious prognostic model for predicting the risk of neonatal respiratory distress (NRD) in preterm and term infants with CPM, based on the prenatal attributes of the malformation.

Methods: MALFPULM is a prospective population-based nationally representative cohort including 436 pregnant women. The main predictive variable was the CPM volume ratio (CVR) measured at diagnosis (CVR first) and the highest CVR measured (CVR max). Separate models were estimated for preterm and term infants and were validated by bootstrapping.

Results: In total, 67 of the 383 neonates studied (17%) had NRD. For infants born at term (> 37 weeks, $N=351$), the most parsimonious model included CVR max as the only predictive variable (ROC area: 0.70 ± 0.04 , negative predictive value: 0.91). The probability of NRD increased linearly with increasing CVR max and remained below 10% for CVR max < 0.4. In preterm infants ($N=32$), both CVR max and gestational age were important predictors of the risk of NRD (ROC area: 0.85 ± 0.07). Models based on CVR first had a similar predictive ability.

Conclusions: Predictive models based exclusively on CVR measurements had a high negative predictive value in infants born at term. Our study results could contribute to the individualized general risk assessment to guide decisions about the need for newborns with prenatally diagnosed CPM to be delivered at specialized centers.

INTRODUCTION

Congenital pulmonary malformations (CPMs) are rare diseases mostly diagnosed in the prenatal period, during routine second-trimester ultrasound (US) examinations, as cystic and/or hyperechoic intrathoracic lesions. Different histological entities have been described, including congenital cystic adenomatoid malformations, sequestrations, bronchial atresia, congenital lobar emphysema, and bronchogenic cysts. However, the histological diagnosis of CPM cannot be predicted reliably from US findings alone [1].

Most CPMs are asymptomatic at birth. Retrospective evaluations have revealed a prevalence of neonatal symptoms of 22-25% [2-4]. The reported prevalence is lower, at about 9-17%, if the outcome is defined by the need for ventilatory support [3-8]. The true prevalence of symptomatic CPM may be even lower, as these retrospective and, often, single-center studies may not have taken all prenatally diagnosed CPMs into account, particularly the smaller ones. However, these evaluations have highlighted that planned delivery at tertiary centers with neonatal intensive care and surgery units is frequent, but not justified for the vast majority of children with CPMs [9]. An important obstacle to preventing the overuse of tertiary services for newborns with CPMs is the lack of prognostic models for the reliable identification of those at low risk of NRD based on prenatal data.

A few retrospective studies have shown that the volume of the malformation in the fetus, estimated by the CPM volume ratio (CVR), is a significant risk factor for NRD [3, 5, 6, 10]. However, heterogeneous definitions of NRD and the inclusion of a large proportion of preterm infants with NRD are major limitations of these studies, making it impossible to assess the relationship between CVR and the risk of NRD in a consistent manner. Moreover, these studies did not consider the added value of other prenatal ultrasound parameters, such as mediastinal deviation, hydramnios, ascites, or other signs of compression, for predicting the risk of NRD.

We conducted a nationally representative prospective cohort study, the MALFPULM cohort, which included more than 400 cases well-phenotyped from the time of prenatal diagnosis. Based on the initial results of this study, we have already been able to define the prenatal course of these malformations [11]. In the present study, our objectives were: i) To develop a parsimonious prognostic model for predicting the risk of NRD in preterm and term infants with CPMs from the prenatal characteristics of the malformation and ii) To identify term newborns at low risk of NRD, not necessarily requiring delivery at a tertiary center.

METHODS

Data source

In France, pregnant women needing a prenatal diagnosis are referred to “multidisciplinary centers for prenatal diagnosis” (MCPDs). MCPDs are accredited by the French health authorities and provide expertise in various aspects of prenatal diagnosis: clinical, laboratory and imaging studies. In particular, all MCPDs have very experienced experts in prenatal US, all of whom hold the national diploma for fetal US.

The MALFPULM study is based on a prospective, nationally representative cohort of prenatally diagnosed CPMs in France. Inclusions took place between March 2015 and June 2018, at 35 MCPDs. This study was approved by an institutional review board (*Comité de Protection des Personnes Ile-de-France IV*, US Department of Health and Human Services Agreement No. 00003835).

The MALPULM cohort has been described in detail elsewhere [11]. Briefly, all pregnant women referred to a MCPD for the prenatal diagnosis of a CPM in the fetus were invited to participate in the study. At inclusion, and at each subsequent visit until delivery, standardized clinical and US data were collected and entered in an electronic case report form, with complete anonymization. As this study required no change to routine clinical care, the numbers of visits and US examinations were not standardized and could differ between

women seen at different centers. The identification of potentially associated malformations on US was not an exclusion criteria.

All investigators used the same definitions to describe the phenotypic appearance of the CPM, and to estimate CPM volume (Supplementary material). For analysis, CPMs were classified as cystic/mixed (with at least one measurable cyst) or hyperechoic (no measurable cyst), according to phenotypic appearance on the first US examination. The CVR was obtained by dividing CPM volume by head circumference. CVR at first US examination after inclusion (CVR first) and the highest CVR value measured during pregnancy (CVR max) were analyzed.

Study population

We initially included 436 pregnant women in the study, corresponding to 1742 prenatal visits and 1674 US examinations. Fifty-three women were excluded from the final analysis, because of fetal death *in utero* or pregnancy termination ($n=10$), missing CVR measurement data ($n=42$), or missing data for respiratory distress ($n=1$) (Figure 1). The final study population therefore comprised 383 women and 1219 US examinations. The characteristics of the final study population and of the women excluded from the study population are shown in Table S1 (Supplementary material).

Outcome definition

A newborn was classified as having NRD if he or she met at least one of the following criteria: persistence, 15 minutes after delivery, of polypnea $> 60/\text{min}$ or signs of retraction (Silverman score greater than or equal to 2); need for oxygen therapy, non-invasive ventilatory support or invasive ventilatory support; need for surgical removal of the CPM before the age of seven days.

In France, the recommendations for newborn care in the delivery room are those currently promoted by the French Society of Neonatology, and which are regularly updated by ILCOR/ERC (International Liaison Committee on Resuscitation/European Resuscitation Council) [12], and were those used by the different teams participating to the study

Statistical analysis

Data were expressed as mean \pm standard deviation (SD). We compared the characteristics of the babies with and without NRD in Chi² tests, Fisher's exact tests and *t*-tests. We used univariable and multivariable logistic regression models to investigate the adjusted and unadjusted associations between the CPM and patient characteristics of NRD. All analyses were conducted separately for preterm and term newborns. Our first model included CVR max as the sole predictive variable, whereas the second model included CVR together with gestational age, malformation type (cystic or non-cystic), and signs of compression (mediastinal shift, polyhydramnios, ascites, eversion of the diaphragm, hydrothorax, hydrops) during pregnancy. Cesarean section is known to be an independent risk factor for NRD, particularly in infants born at term, but we decided not to include this parameter in the models for the main analysis of the study, because our aim was to develop a predictive model for use in the prenatal period. It therefore needed to be independent of the type of delivery actually practiced at the end of the pregnancy. Nevertheless, as a complementary analysis, we also estimated a model including cesarean section as an additional predictor of NRD. Predictive ability was measured by assessing model discrimination (ROC), calibration (Hosmer-Lemeshow goodness-of-fit test), sensitivity, specificity, positive and negative predictive values. Bootstrapping was then performed for model validation.

The classification thresholds for predictive models were defined with the Youden test, to optimize the relationship between false-positive and true-positive rates. We performed the same set of analyses on CVR first and on CVR max. We also looked at the changes in CVR over time (i.e. as a function of gestational age) for newborns with and without NRD, separately for term and preterm infants. A population-average (generalized estimating equations) logistic regression analysis was performed. All analyses were performed with Stata v14 (StataCorp, College Station, TX, USA).

To verify that missing data did not alter our conclusions, we performed a multiple imputation by chained equations (MICE) using the variables respiratory distress, CVR, type of malformation and sign of compression during pregnancy to create 10 imputed datasets; we used augmented regression approach due to the presence of perfect prediction.

Further, we verified the potential variance in our composite primary outcome (respiratory distress that includes O₂ administration, invasive or non-invasive ventilation and surgery) across 35 centers by using a random intercept multilevel logistic regression model.

RESULTS

In total, 383 women, with a mean of 4.0 ± 1.9 US examinations each, were included in the study (Table S1). Characteristics of the population are described Table 1. Most of the CPM lesions were small, with a median CVR max value of 0.41 (Supplementary Figure S1). At least one sign of compression was observed during the pregnancy for 170 fetuses (Table S2).

Neonatal respiratory distress

In total, 67 (17%) neonates were considered to have respiratory distress, as they met at least one of the criteria of the definition used. Polypnea or signs of retraction persisted 15 minutes after the delivery in 29 neonates, 45 neonates required oxygen therapy, 46 required non-invasive ventilatory support, 10 required mechanical ventilation, and 15 required surgical removal of the CPM before the age of 7 days. Overall, 55 of the 67 neonates required oxygen therapy or ventilatory support.

NRD was significantly associated with preterm birth, cesarean section, higher CVR at first US examination, higher maximal CVR value, higher rate of signs of compression on US, and a greater need for fetal therapy (Table 1). CVR max was reached significantly later in the pregnancy for the cases that went on to develop NRD. Only signs of compression other than mediastinal deviation were associated with the risk of NRD (Supplementary Table S2).

Estimation of models based on continuous CVR max in term infants

Fractional polynomial modeling of changes in CVR with increasing gestational age between CPM diagnosis and delivery revealed clearly different patterns between children with and without NRD (Figure 2). Term infants without NRD were characterized during pregnancy by a lower CVRmax and a decrease in the volume of their malformation in late pregnancy. Univariate analyses and adjusted odds ratio for the predictors of respiratory distress in term infants are presented in Table 2. CVR max and prenatal signs of compression on US were significant predictors of NRD in infants born on term in univariate analyses, whereas cystic phenotype and gestational age were not predictive in this model. The OR for each one-tenth increase in CVR max was 1.14 (95% CI :1.09-1.19). The adjusted model identified CVR max as the sole independent predictor, with an aOR (95% CI) of 1.13 (1.07-1.20).

We then compared the performance of the adjusted model to that of a simple model based exclusively on CVR max. If positive cases were classified as those with a predicted probability of NRD of 0.15 or more, according to the Youden test, the two models for infants born at term had similar performances in terms of sensitivity, specificity, positive predictive value, negative predictive value, and area under the ROC (Table 3). The rate of correctly classified cases was 79% with the adjusted model, and 77% with the simple model (Supplementary Table S3).

Lowering the classification threshold to a probability of NRD of at least 0.10 increased sensitivity to 65%, lowered specificity to 55%, and maintained the negative predictive value at 90% (Supplementary Table S4).

Fractional polynomial modeling of the risk of NRD according to CVR max revealed a gradual, almost linear rise in NRD risk with increasing CVR max, with no threshold effect (Figure 3). Calibration tests and bootstrapping validated the model. The area under the ROC for this model after bootstrapping was 0.71 (95% CI: 0.62; 0.79) with a *p* value for the Hosmer-Lemeshow test of 0.472 (Supplementary Figure S2). The addition of cesarean section to a model already including CVR max and the other prenatal predictor variables improved model discrimination, with an area under the ROC of 0.79 (95% CI: 0.71 ; 0.86). The negative predictive value of the model also increased slightly, from 0.90 to 0.95 (Supplementary Table S5).

Missing data did not influence our results. We did not find any difference between the model's estimates before and after using multiple imputation by chained equations (MICE). Further, we did not find a significant difference across the 35 centers using a likelihood-ratio test to compare the multi-level regression model with our basic logistic regression model (variance{center} = 0.26 [0.02; 4.18], *pr* = 0.187)).

Estimation of the model based on continuous CVR max in preterm infants

Univariate analyses and adjusted odds ratio for the predictors for respiratory distress are presented in Table S6. Due to the small number of premature neonates, the confidence intervals obtained were large and CVR max was of borderline significance in univariate analysis ($p=0.054$). As for term infants, polynomial modeling revealed a very gradual increase in the risk of NRD with increasing CVR max (Figure 3). However, because of the inherent risk of NRD due to premature birth, the probability of developing NRD was about 0.3 for the lowest values of CVR max. The performances of the simple and adjusted models for preterm neonates are shown in Table 4. Overall, 79% of the cases were correctly classified with the adjusted model, and 69% with the simple model (Supplementary Table S7). The area under the ROC for the simple model after bootstrapping was 0.727 ± 0.096 (CI: 0.538; 0.915) (Supplementary Figure S2), with p values of 0.879 and 0.470 for the Hosmer-Lemeshow test and Pearson's test, respectively.

Estimation of the model based on continuous CVR first

We investigated whether a model based on the first CVR measurement after prenatal diagnosis could provide a predictive performance similar to that of a model based on the maximum CVR value measured during pregnancy. Fractional polynomial modeling of the risk of NRD according to CVR first gave results very similar to those obtained with CVR max (Figure 3). The performances of the simple and adjusted models in preterm neonates are shown in Table 3.

DISCUSSION

Using data from a large, nationally representative, prospective cohort of children with prenatally diagnosed CPM, we aimed to develop a parsimonious predictive model that could be used for risk stratification for newborns with CPM, making it possible to identify the infants with a low risk of NRD, not necessarily requiring delivery at a tertiary center.

In our study, NRD was defined by composite criteria, making it possible to include all newborns with persistent symptoms at birth, the vast majority of whom require oxygen or ventilatory support. The cut off for surgery was arbitrarily set at day 7 of postnatal life, but was unlikely to influence our model, as the small number of children involved (n=15) also had NRD criterion. The 15-minute interval used in our study was able to accurately identify neonates with permanent respiratory distress. Indeed, the 15th postnatal minute is well after all the necessary steps for a gradual management of neonatal respiratory difficulties, as defined by the ILCOR/ERC [12], and this interval integrates the time necessary for the normalization of pre-ductal oxygen saturation after birth [13]. This definition makes it possible to include all newborns who actually need medical supervision, while targeting only a small minority of children: 17% of our study population. As expected, this rate was lower than the 22%-25% rate reported in retrospective studies using a comparable definition of NRD [2-4]. Similarly, less than 3% of newborns in our cohort required invasive ventilation, versus 5-11% in previous retrospective studies [3, 4, 6, 10]. These differences are probably at least partly due to the prospective and population-based design of our study, making it possible to include all prenatally diagnosed CPMs, including the smaller ones. The robustness of the NRD definitions used in our study is reflected in the homogeneity of the results between centers, evidenced by the absence of variance in our composite primary outcome across the 35 centers, using a random intercept multilevel logistic regression model.

The volume of the CPM, as measured by the CVR, was highly significantly associated with the risk of NRD in our cohort. CVR was first developed as a tool for predicting serious prenatal complications of CPM, such as hydrops [14]. Several studies have shown prenatal CVR measurements to be predictive of the risk of NRD [3-6, 10, 15, 16]. A recent systematic review analyzed 11 studies with neonatal respiratory endpoints [17]. Indirect signs of compression on US, such as polyhydramnios, eversion of the diaphragm, ascites or hydrops, were also found to be significantly associated with NRD in our population. However, given the strong causal relationship between CVR and these signs of compression, CVR alone had essentially the same predictive ability, including a negative predictive value > 90%, and adding signs of compression to a model already including CVR was of no added value for prediction by the model.

Studies evaluating the predictive value of CVR have used either the maximum value of CVR during pregnancy or the initial value of CVR at diagnosis [17]. Our results are encouraging, in that models based on CVR max and CVR first had very similar predictive abilities, suggesting that CVR first is a potentially useful predictor of the pre- and postnatal prognosis of fetuses with CPM. Indeed, malformations associated with a low risk of NRD have a very low growth potential, with a lower CVR first, and a CVR max occurring early in the pregnancy and only slightly higher than CVR first.

One of the most important findings of this study was the demonstration of a linear dose-response relationship between first (or maximum) CVR values and the risk of NRD, for both term and preterm infants. Several previous studies sought to identify various thresholds for CVR values that could discriminate between cases at high and low risk of complications [17]. Only one of these studies proposed a predictive model for invasive respiratory support at birth, but its results were limited by the small number of cases with this complication ($n=16$), with more than two-thirds of them born prematurely [6]. This study nevertheless showed that

a discriminant model performed better than simple cutoffs based on CVR max [6]. Our study has the advantage of including sufficient cases for stratification between fetuses carried to term and those born preterm. We found that the risk of NRD in term infants was below 10%, provided that CVR max remained below about 0.40 (with small differences between CVR max and CVR first). The distribution of CVR max values in the term infants in our study revealed that almost half the fetuses with CPMs had CVR max values below 0.40. Our model also provides an estimate of the probability of the CPM contributing to NRD in preterm infants. It is important for the neonatologist to assess the potential contribution of the CPM to NRD in preterm infants, and our models demonstrate that such a contribution is most likely in cases in which CVR max or initial CVR is high. The comparison of our model with other retrospective studies proposing CVR thresholds to predict the risk of DRN is often difficult because of variable definitions of neonatal respiratory symptoms, and/or frequent biases related to a large proportion of premature infants in the study population, and/or a more limited inclusion of small malformations, as evidenced by much higher CVR mean or median values in the populations of these studies [6, 16]. This last point may notably artificially shift the CVR thresholds given by ROC curves towards higher values. Other studies with more comparable populations have proposed CVRmax thresholds that may appear relatively high compared to our current results, but which are actually fully consistent with our model. For example, in our previous study, based on French referral center recruitments, a CVR threshold of 0.84 was proposed to discriminate between children without neonatal respiratory distress and those with neonatal respiratory distress [3]. Among children with $CVR < 0.84$, 14% had had neonatal symptoms, in full consistency with the average risk of 15% of DRN predicted by our current model for this CVRmax value. The major advantage of our model is that it can assess the risk of DRN for a given CVR value, which is not possible with studies based on a single threshold. However, it must be underlined that the low prevalence (pre-test probability)

of respiratory distress in term newborns with pulmonary malformation was responsible for a limited absolute difference between pre-test and post-test probability of not having neonatal respiratory distress in these neonates. By contrast, the absolute difference in the positive pre- and post-test probabilities was much higher, with a difference of 17%. Therefore, although our model allows for a better targeting of children at low risk of neonatal respiratory distress, it cannot alone summarize the decision of the place of birth, which must take into account the specific aspects of each situation, as well as the local particularities of the health care pathway.

Cesarean section is a known risk factor for NRD in term infants, even in low-risk pregnancies [18], and can, therefore, be considered an intrinsic risk factor for NRD in infants born at term, regardless of the rest of their history. Indeed, the addition of cesarean section to the model including CVR and other predictive variables improved model discrimination and, to a lesser extent, negative predictive value. However, we prefer to favor our parsimonious “prenatal” model (i.e. based on CVR max/CVR first and not including the type of delivery) for two reasons; the negative predictive value of this model exceeded 90% and the intended use of this model was primarily in risk stratification for infants with CPM born at term. The rate of cesarean section was 16% in our study, below the 20% rate reported for the general population in France [19]. We can therefore conclude that the prenatal diagnosis of CPM did not increase the frequency of elective cesarean section.

The persistence of false negatives despite the consideration of delivery by cesarean section may reflect other reasons for NRD in term infants entirely unrelated to CPM. It may also suggest that prenatal factors other than CPM volume may contribute to NRD in infants born at term. It is possible that more diffuse abnormalities of airway development are present in these children, potentially contributing to a higher frequency of neonatal respiratory

morbidity, regardless of the size of the malformation. Such hypotheses have already been proposed to explain the high frequency of bronchial hyperreactivity in infants [2].

In conclusion, this study shows that, in infants born at term, predictive models based on initial or maximum values of CVR alone are of high negative predictive value. CVR max values below 0.40 were associated with a risk of NRD of less than 10% in term infants with CPM. Our study results can therefore guide decisions about the need for infants with prenatally diagnosed CPM to be delivered at specialized centers. Such decision must however take into account not only the CPM data, but also the general risk assessment of a specific mother-infant dyad in pregnancy, including local policies and structures.

Acknowledgements

MALFPULM study group

Name	City	email
Florence BIQUARD	CHU Angers	flbiquard@chu-angers.fr
Jean-Paul BORY	CHU Reims	jpbory@chu-reims.fr
François GOFFINET	AP-HP, Cochin-Port Royal, Paris	francois.goffinet@aphp.fr
Valat-Rigot AS	CH Lens	asvalat@ch-lens.fr
Norbert Winer	CHU Nantes	norbert.winer@chu-nantes.fr
Eve MOUSTY	CHU Nîmes	eve.mousty@chu-nimes.fr
Charles MUSZYNSKI	CHU Amiens	muszynski.charles@chu-amiens.fr
Fabienne PRIEUR	CHU St Etienne	fabienne.prieur@chu-st-etienne.fr
Thibaud QUIBEL	CH Poissy	thibquib@hotmail.com
Claudine TOUBOUL	CHI Créteil	claudine.touboul@chicreteil.fr
Jean GONDROY	CHU Amiens	gondroy.jean@chu-amiens.fr
Loic SENTILHES	CHU Bordeaux	loic.sentilhes@chu-bordeaux.fr
Valérie BONFIGLIOLI Lionel CARBILLON	APHP, Bondy	valerie.bonfiglioli@aphp.fr lionel.carbillon@aphp.fr
anne-helene Saliou	CHU Brest	anne-helene.saliou@chu-brest.fr
Julien SAADA Alexandra LETOURNEAU	APHP, Clamart	julien.saada@gmail.com letourneau.alexandra@aphp.fr
Helene LAURICHESSE	CHU Clermont-Ferrand	helaurichesse@chu-clermontferrand.fr
Carole EGRON	CHU Clermont-Ferrand	cegron@chu-clermontferrand.fr
Loren DESLANDES	CHU Clermont-Ferrand	ldeslandes@chu-clermontferrand.fr
Vanina CASTAIGNE	CHI Créteil	Vanina.Castaigne@chicreteil.fr
Christophe PIOLAT	CHU Grenoble	cpiolat@chu-grenoble.fr
Claire DAZEL-SALONNE	CH Le Mans	csalonne@ch-lemans.fr
Julien STIRNEMANN Philippe ROTH Thierry BULTEZ Yves Ville	APHP, Necker, Paris	julien.stirnemann@aphp.fr philippe.roth@aphp.fr thierry.bultez@aphp.fr yves.ville@aphp.fr
Vassilis TSATSARIS	APHP, Cochin, Paris	vassilis.tsatsaris@aphp.fr
Lucie GUILBAUD	APHP, Trousseau, Paris	lucie.guilbaud@aphp.fr
Anne-Marie DARRAS	APHP, Trousseau, Paris	anne-marie.darras@aphp.fr
Jean-Francois OURY	APHP, Robert Debré, Paris	jean-francois.oury@aphp.fr
BERTORELLO (SF)	CHU Rennes	SF5106@chu-rennes.fr
Cecile FANGET	CHU St Etienne	cecile.fanget@chu-st-etienne.fr
Romain FAVRE	CHU Strasbourg	romain.favre@chru-strasbourg.fr

Anne PARIS	Talence (Maison de santé protestante Bordeaux Bagatelle)	a.paris@mspb.com
Franck PERROTIN	CHU Tours	franck.perrotin@med.univ-tours.fr
Nathalie BANASZKIEWICZ	CHU Nantes	nathalie.banaszkiewicz@chu-nantes.fr
Thameur RAKZA	CHU Lille	thameur.rakza@chru-lille.fr
Mathieu MORIN	CHU Toulouse	morin.m@chu-toulouse.fr
Cynthia TRASTOUR	CHU Nice	trastour.c@chu-nice.fr
Nicolas MOTTET	CHU Besançon	ncmottet@gmail.com
Frederic COATLEVEN	CHU Bordeaux	frederic.coatleven@chu-bordeaux.fr
Elisabeth ALANIO	CHU Reims	ealanio@chu-reims.fr
Olivier MOREL Estelle PERDRIOLLE	CHU Nancy	olivier.morel@chru-nancy.fr e.perdriolle-galet@chu-nancy.fr
Marie-Laure ESZTO-CAMBON	CHR Metz	ml.eszto@chr-metz-thionville.fr
Loreto Naya Aquilue	APHP, URC Necker	loreto.naya@aphp.fr
Celine Hauw	APHP, URC Necker	celine.hauw@aphp.fr
Guillaume Podevin	CHU Angers	GuPodevin@chu-angers.fr
Hala Feghali	CHU Bordeaux	hala.feghali@chu-bordeaux.fr
Caroline Thumerelle	CHU Lille	caroline.thumerelle@chru-lille.fr
Rafaelle Mangione	Bordeaux	r1mang@aol.com
Marie-Noelle Lebras	APHP, Robert Debré, Paris	marie-noelle.lebras@aphp.fr
Rony Sfeir	CHRU Lille	Rony.SFEIR@CHRU-LILLE.FR
Héloïse Ducoin	CH Lens	hducoin@ch-lens.fr
Bernard Romeo	CHU Amiens	Romeo.Bernard@chu-amiens.fr
Philippe Buisson	CHU Amiens	buisson.philippe@chu-amiens.fr
Pierrick Cros	CHU Brest	pierrick.cros@chu-brest.fr
Philine Devries	CHU Brest	philine.devries@chu-brest.fr
Jacques Brouard	CHU Caen	brouard-j@chu-caen.fr
Thierry Petit	CHU Caen	petit-t@chu-caen.fr
Guenolee Delambert	APHP, Bicêtre	guenolee.delambert@aphp.fr
Isabelle Petit	CHU Clermont-Ferrand	ipetit@chu-clermontferrand.fr
Adam Kandem Simo	CHU Clermont-Ferrand	akamdemsimo@chu-clermontferrand.fr
Maguelonne Pons	CHU Clermont-Ferrand	mpons@chu-clermontferrand.fr
Olivier Jaby	CHI Créteil	olivier.jaby@chicreteil.fr
Catherine Llerena	CHU Grenoble	CLlerena@chu-grenoble.fr
Edith Sabatier	CHU Nîmes	edith.SABATIER@chu-nimes.fr
Guillaume Thouvenin	APHP, Trousseau, Paris	guillaume.thouvenin@aphp.fr
Michele Larroquet	APHP, Trousseau, Paris	michele.larroquet@aphp.fr
Sabine Irtan	APHP, Trousseau, Paris	sabine.irtan@aphp.fr

Christine Grapin	APHP, Robert Debré, Paris	christine.grapin@aphp.fr
Guillaume Levard	CHU Poitiers	guillaume.levard@chu-poitiers.fr
Sylvaine Lefeuvre	CHU Rennes	sylvaine.lefeuvre@chu-rennes.fr
Edouard Habonimana	CHU Rennes	edouard.habonimana@chu-rennes.fr
Caroline Parico	CHU St Etienne	caroline.paricio@chu-st-etienne.fr
François Varlet	CHU St Etienne	francois.varlet@chu-st-etienne.fr
Jacqueline Matis	CHRU Strasbourg	jacqueline.matis@chru-strasbourg.fr
François Becmeur	CHRU Strasbourg	francois.becmeur@chru-strasbourg.fr
Isabelle Gibertini	CHU Tours	I.GIBERTINI@chu-tours.fr
Hubert Lardy	CHU Tours	hubert.lardy@univ-tours.fr
Stephan Denapolicocci	CHU Nantes	Stephan.DENAPOLICOCCI@chu-nantes.fr
Antoine Deschildre	CHRU Lille	antoine.deschildre@chru-lille.fr
Jean Breaud	CHU Nice	BREAUD.J@pediatrie-chulenvall-nice.fr
Jean-François Lecompte	CHU Nice	lecompte.j@pediatrie-chulenvall-nice.fr
Aurelie Camelio	CHU Besançon	acamelio@chu-besancon.fr
Arnaud Fotso Kamdem	CHU Besançon	afotsokamdem@chu-besancon.fr
Frédéric Elbaz	CHU Rouen	Frederic.Elbaz@chu-rouen.fr
Frédéric Lavrand	CHU Bordeaux	Frederic.lavrand@chu-bordeaux.fr
Mickael Pomedio	CHU Reims	mpomedio@chu-reims.fr
Francis Lefebvre	CHU Reims	flefebvre@chu-reims.fr
Jean Louis Lemelle	CHU Nancy	jl.lemelle@chu-nancy.fr
Vladimir Gomola	CHU Metz-Thionville	v.gomola@chr-metz-thionville.fr
François BREMONT	CHU Toulouse	bremont.f@chu-toulouse.fr

REFERENCES

1. Hadchouel A, Benachi A, Revillon Y, et al. Factors associated with partial and complete regression of fetal lung lesions. *Ultrasound Obstet Gynecol* 2011; 38: 88-93.
2. Delestrain C, Khen-Dunlop N, Hadchouel A, et al. Respiratory Morbidity in Infants Born With a Congenital Lung Malformation. *Pediatrics* 2017; 139:e20162988
3. Ruchonnet-Metrailler I, Leroy-Terquem E, Stirnemann J, et al. Neonatal outcomes of prenatally diagnosed congenital pulmonary malformations. *Pediatrics* 2014; 133: e1285-91.
4. Tuzovic L, Copel JA, Stitelman DH, et al. Utility of Fetal Cardiac Axis and Cardiac Position Assessment in Predicting Neonatal Respiratory Morbidity in Fetal Congenital Lung Lesions. *J Ultrasound Med* 2019; 38: 2361-2372.
5. Ehrenberg-Buchner S, Stapf AM, Berman DR, et al. Fetal lung lesions: can we start to breathe easier? *Am J Obstet Gynecol* 2013; 208: 151 e1-7.
6. Eyerly-Webb S, Nicolas CT, Watson D, et al. Dynamic discriminant model for predicting respiratory distress at birth based on mass volume ratio in fetuses with congenital lung malformation. *Ultrasound Obstet Gynecol* 2019; 54: 759-766.
7. Girsen AI, Hintz SR, Sammour R, et al. Prediction of neonatal respiratory distress in pregnancies complicated by fetal lung masses. *Prenat Diagn* 2017; 37: 266-272.
8. Ng C, Stanwell J, Burge DM, et al. Conservative management of antenatally diagnosed cystic lung malformations. *Arch Dis Child* 2014; 99: 432-7.
9. Greig CJ, Keiser AM, Cleary MA, et al. Routine postnatal chest x-ray and intensive care admission are unnecessary for a majority of infants with congenital lung malformations. *J Pediatr Surg* 2019; 54: 670-674.
10. Kane SC, Da Silva Costa F, Cramer JA, et al. Antenatal assessment and postnatal outcome of fetal echogenic lung lesions: a decade's experience at a tertiary referral hospital. *J Matern Fetal Neonatal Med* 2019; 32: 703-709.
11. Delacourt C, Bertille N, Salomon LJ, et al. Prenatal natural history of congenital pulmonary malformations: MALFPULM population-based cohort study. *Ultrasound Obstet Gynecol* 2019; 54: 381-388.
12. Wyckoff MH, Wyllie J, Aziz K, et al. Neonatal Life Support: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation* 2020; 142: S185-S221.

13. Mariani G, Dik PB, Ezquer A, et al. Pre-ductal and post-ductal O₂ saturation in healthy term neonates after birth. *J Pediatr* 2007; 150: 418-21.
14. Crombleholme TM, Coleman B, Hedrick H, et al. Cystic adenomatoid malformation volume ratio predicts outcome in prenatally diagnosed cystic adenomatoid malformation of the lung. *J Pediatr Surg* 2002; 37: 331-8.
15. Riley JS, Urwin JW, Oliver ER, et al. Prenatal growth characteristics and pre/postnatal management of bronchopulmonary sequestrations. *J Pediatr Surg* 2018; 53: 265-269.
16. Kunisaki SM, Saito JM, Fallat ME, et al. Fetal Risk Stratification and Outcomes in Children with Prenatally Diagnosed Lung Malformations: Results from a Multi-Institutional Research Collaborative. *Ann Surg* 2020; Online ahead of print
17. Kane SC, Ancona E, Reidy KL, et al. The Utility of the Congenital Pulmonary Airway Malformation-Volume Ratio in the Assessment of Fetal Echogenic Lung Lesions: A Systematic Review. *Fetal Diagn Ther* 2020; 47: 171-181.
18. Hansen AK, Wisborg K, Uldbjerg N, et al. Risk of respiratory morbidity in term infants delivered by elective caesarean section: cohort study. *BMJ* 2008; 336: 85-7.
19. Blondel B, Coulm B, Bonnet C, et al. Trends in perinatal health in metropolitan France from 1995 to 2016: Results from the French National Perinatal Surveys. *J Gynecol Obstet Hum Reprod* 2017; 46: 701-713.

FIGURE LEGENDS

Figure 1




Figure 1. Flow chart of the study

Figure 2




Figure 2. Fractional polynomial modeling of changes in CVR with increasing gestational age, between CPM diagnosis and birth in term infants (A) without NRD ($n= 943$ US examinations, 300 women, $P<0.001$) or (B) with NRD ($n= 172$ US examinations, 51 women, $P= 0.029$).

Figure 3




Figure 3. Probability of developing NRD in infants born at full term (dark gray) and preterm (light gray) according to CVR max (A. simple model) or CVR first (B. simple model)

Table 1 : Characteristics of the study population. The data shown are means \pm SD or *N* (% of the total of the column). * includes cases with polyhydramnios, eversion of the diaphragm, ascites, hydrothorax, or hydrops. **Fetal therapies included amnioreduction, thoraco-amniotic shunting, or maternal corticosteroid treatment

	No neonatal respiratory distress <i>N</i> =316	Neonatal respiratory distress <i>N</i> =67	Total <i>N</i> =383	<i>P</i> value
Sex (male)	179 (57)	37 (55)	216 (56)	0.831
Gestational age at first CVR determination	23.3 \pm 3.8	24.0 \pm 4.6	23.5 \pm 3.9	0.183
Gestational age at CVR max	25.7 \pm 4.2	27.3 \pm 4.9	25.9 \pm 4.4	0.006
Gestational age at birth (weeks)	39.6 \pm 1.4	38.3 \pm 2.7	39.4 \pm 1.8	<0.001
Preterm birth	16 (5)	16 (24)	32 (8)	<0.001
Cesarean section	40 (13)	23 (34)	63 (16)	<0.001
Birth weight (kg)	3.32 \pm 0.49	3.14 \pm 0.68	3.28 \pm 0.53	0.017
Phenotype of the CPM				0.612
Cystic/mixed	175 (55)	38 (57)	213 (56)	
Hyperechoic	139 (45)	38 (43)	168 (44)	
Location of the malformation at inclusion				0.577
Right	136 (43)	33 (50)	169 (44)	
Left	175 (56)	32 (48)	207 (54)	
Bilateral	4 (1)	1 (2)	5 (1)	
Systemic vascularization during pregnancy	113 (36)	18 (27)	131 (34)	0.163
CVR at the first US exam	0.44 \pm 0.42	0.96 \pm 0.94	0.53 \pm 0.58	<0.001
CVR max	0.54 \pm 0.48	1.26 \pm 1.13	0.67 \pm 0.70	<0.001
CVR max (median, min-max)	0.41 [0.00-2.60]	0.83 [0.01-4.89]	0.44 [0.00-4.89]	
Signs of compression during pregnancy				<0.001
No	191 (60)	22 (33)	213 (56)	
Mediastinal shift only	92 (29)	18 (27)	110 (29)	
Others*	33 (10)	27 (40)	60 (16)	
Fetal therapy**	8 (3)	14 (21)	22 (6)	<0.001

Table 2. Estimation of the model based on continuous CVR max for infants born at full term.
uOR: univariate odds ratio; aOR: adjusted odds ratio

Variable	uOR	95% CI	<i>p</i> value	aOR	95% CI	<i>p</i> value
Gestational age	0.87	0.67-1.12	0.274	0.95	0.72 - 1.27	0.750
Cystic/mixed CPM	1.08	0.59-1.98	0.793	0.82	0.42 – 1.61	0.562
CVR max *	1.14	1.09-1.19	<0.001	1.13	1.07 – 1.20	<0.001
Signs of compression during pregnancy						
No	Ref			Ref		
Mediastinal shift only	1.63	0.79-3.38	0.189	0.75	0.32 – 1.75	0.504
Others	6.43	2.99-13.82	<0.001	1.64	0.58 – 4.65	0.352

*Odds ratio for an increase of 0.1 in CVR

Table 3. Performance of the simple and full adjusted models for full-term births and preterm births. Models were estimated on the basis of continuous CVR max or continuous first CVR. Cases were considered positive if the predicted probability of NRD was at least 0.15 for births at full term, and at least 0.45 for preterm births. True-positive cases were those for which NRD actually occurred. ROC Area is the area under the ROC obtained after bootstrapping.

	Full-term birth				Preterm birth			
	CVR max		First CVR		CVR max		First CVR	
	Simple	Full	Simple	Full	Simple	Full	Simple	Full
ROC Area	0.70	0.71	0.69	0.70	0.73	0.85	0.71	0.84
	± 0.04	± 0.05	± 0.04	± 0.05	± 0.09	± 0.07	± 0.10	± 0.08
Sensitivity	0.51	0.55	0.45	0.57	0.69	0.77	0.62	0.77
Specificity	0.81	0.83	0.79	0.81	0.69	0.80	0.75	0.80
Positive predictive value	0.32	0.35	0.26	0.33	0.69	0.77	0.71	0.77
Negative predictive value	0.91	0.92	0.89	0.92	0.69	0.80	0.67	0.80

**Predicting the risk of respiratory distress in newborns with prenatally diagnosed
congenital pulmonary malformations:**

The MALFPULM prospective population-based cohort study

Christophe DELACOURT, MD, PhD^{1,2}, Nathalie BERTILLE, PhD³, Laurent J. SALOMON,
MD, PhD^{2,4}, Makan RASHENAS, MD, MPH³, Alexandra BENACHI, MD, PhD⁵, Arnaud
BONNARD, MD, PhD⁶, François BREMONT, MD⁷, Laure CHOUPEAUX, MSc⁸, Virginie
FOUQUET, MD⁹, Valérie GOUA, MD¹⁰, Frédéric HAMEURY, MD¹¹, Erik HERVIEUX¹², Jean-
Marie JOUANNIC, MD, PhD¹³, Naziha KHEN-DUNLOP, MD, PhD¹⁴, Gwenaëlle LE BOUAR,
MD¹⁵, Jérôme MASSARDIER, MD, PhD¹⁶, Jonathan ROSENBLATT, MD, PhD¹⁷, Agnès
SARTOR, MD¹⁸, Catherine THONG-VANH, MD¹⁹, Nathalie LELONG, MSc³, Babak
KHOSHNOOD, MD, PhD³, for the prenatal MALFPULM study group*

SUPPLEMENTARY MATERIAL

Prenatal phenotypic description of the CPM

Systemic vascular supply was assessed by color and power Doppler US. Given the difficulty predicting the histological type of the CPM based solely on the US examination, only phenotypic description data for the malformation were collected. All investigators used the following common definitions for the phenotypic appearance of the CPM. Lesions displaying hyperechogenicity with no measurable cyst were classified as "hyperechoic lesions". A lesion with measurable cysts in the lung, and no hyperechogenicity around the cysts was considered a "purely cystic lesion". Finally, a lesion with at least one measurable cyst in a hyperechoic lung was described as a "mixed lesion".

The following US parameters were also collected at each examination: fetal biometry data, dimensions of the malformation (length, width, height), indirect signs of compression (mediastinal shift, eversion of the diaphragm, hydrothorax, ascites, polyhydramnios, hydrops) and associated systemic vascularization. Mediastinal shift was defined as the deviation of the mediastinal structures towards one side of the thorax, with or without a change in cardiac axis, and was included in the definition of compression, because of the demonstration that this US sign was itself a significant risk factor for respiratory distress at birth (Ruchonnet-Metrailler et al, 2014).

Polyhydramnios was defined as an amniotic fluid index of 25 cm or more and/or a deepest amniotic pool of 10 cm or more. Eversion of the diaphragm was defined as an inversion in the normal convexity of the diaphragm. Hydrothorax was defined as the presence of a pleural effusion of at least 5 mm. The maximal height of the lesion was first measured in the sagittal plane. The maximal dimensions of the lesion were then measured in the plane perpendicular to this axis. From the US data, CPM volume was estimated with the formula for a prolate ellipse ($L \times H \times W \times 0.52$). The CVR was obtained by dividing the CPM volume

by the head circumference (HC). The HC was measured in the axial plane at the level of the cavum septum pellucidum.

Table S1. Comparison between included and excluded cases in the eligible population. The data shown are the mean \pm SD or *N* (% of the total of the column)

	Eligible population			
	Excluded (<i>n</i> =43)	Included (<i>n</i> =383)	Total (<i>n</i> =426)	<i>P</i> value
Maternal age at inclusion	31.0 \pm 4.8	30.3 \pm 5.2	30.4 \pm 5.1	0.379
US phenotype of the malformation: cystic/mixed	31 (72)	213 (56)	244 (57)	0.008
No. of ultrasound scans	2.1 \pm 0.9	4.0 \pm 1.9	3.6 \pm 2.2	<0.001
No. of visits	2.2 \pm 1.2	4.1 \pm 2.0	3.9 \pm 3.7	<0.001
Signs of compression during pregnancy				0.670
No	24 (56)	213 (56)	237 (56)	
Mediastinal deviation only	9 (21)	110 (29)	119 (28)	
Others	5 (12)	60 (16)	65 (15)	
Systemic vascularization during pregnancy	8 (19)	131 (34)	139 (33)	0.107
Location of the malformation				0.697
Right	18 (42)	169 (44)	187 (44)	
Left	25 (58)	207 (54)	232 (54)	
Bilateral	0 (0)	5 (1)	5 (1)	

Table S2: Other signs of fetal compression and association with neonatal respiratory distress

	No neonatal respiratory distress <i>N</i> =316	Neonatal respiratory distress <i>N</i> =67	Total <i>N</i> =383	<i>P</i> value
Eversion of the diaphragm	23 (7)	12 (18)	35 (9)	0.010
Ascites	2 (1)	8 (12)	10 (3)	<0.001
Polyhydramnios	8 (3)	10 (15)	18 (5)	<0.001
Hydrothorax	5 (2)	8 (12)	13 (3)	<0.001
Hydrops	1 (0)	3 (4)	4 (1)	0.018

Table S3. Performance of the simple and adjusted models for full-term births. Distribution of cases, with classification as positive if the probability of neonatal respiratory distress predicted by the model was 0.15 or more (empirical cutoff estimated with the Youden test, simple=0.14; adjusted=0.15). True-positive cases were those that went on to develop NRD.

Classified	Simple model			Adjusted Model		
	Distress (NRD ⁺)	No distress (NRD ⁻)	Total	Distress (NDR ⁺)	No distress (NRD ⁻)	Total
+	29	63	92	28	51	79
-	22	237	259	23	248	271
Total	51	300	351	51	299	350*

*missing data for malformation type

Table S4. Performance of simple and adjusted models for full-term births. Distribution of cases, with classification as positive if the probability of neonatal respiratory distress predicted by the model was 0.10 or more. True positive cases were those that went on to develop NRD.

	CVR max		First CVR	
	Simple	Adjusted	Simple	Adjusted
AUC after bootstrapping	0.70±0.04	0.71±0.04	0.69±0.04	0.70±0.04
Sensitivity	65%	73%	69%	67%
Specificity	55%	60%	54%	58%
Positive predictive value	20%	24%	20%	21%
Negative predictive value	90%	93%	90%	91%

Table S5. Performance of a model integrating both CVRmax and cesarean section for infants born at term. Adjusted OR (95% CI, *p* value) for CVR max (1:10) and cesarean section were 1.1 (1.1-1.2, *p*<0.001) and 4.0 (1.8-8.5, *p*<0.001), respectively. Distribution of cases, with classification as positive if the probability of NRD predicted by the model was 0.15 or more or 0.10 or more. True-positive cases were those that went on to develop NRD.

	Probability of NRD \geq 0.15		Probability of NRD \geq 0.10	
	CVR max alone	CVR max and cesarean section	CVR max alone	CVR max and cesarean section
AUC after bootstrapping	0.70 \pm 0.04	0.79 \pm 0.04	0.70 \pm 0.04	0.79 \pm 0.04
Sensitivity	51%	71%	65%	80%
Specificity	81%	78%	55%	66%
Positive predictive value	32%	35%	20%	29%
Negative predictive value	91%	94%	90%	95%

Table S6. Model estimation based on continuous CVR max for preterm births

Variable	uOR	95% CI	<i>p</i> value	aOR	95% CI	<i>p</i> value
Gestational age	0.5	0.3-0.9	0.034	0.4	0.2-1.1	0.068
Cystic/mixed CPM	2.0	0.5-8.6	0.350	5.7	0.6-55.5	0.136
CVR max (1:10)	1.1	1.0-1.3	0.054	1.1	0.5-1.25	0.277
Signs of compression during pregnancy*						
No	Ref			Ref		
Others	4.9	1.1-24.1	0.048	1.8	0.1-25.5	0.681

*No = Mediastinal shift only

Table S7. Performance of simple and adjusted models for preterm births. Distribution of cases, with classification as positive if the probability of neonatal respiratory distress predicted by the model was 0.45 or more (empirical cutoff estimated with the Liu test simple=0.14; full=0.42; too few cases for the Youden test). True-positive cases were those that went on to develop neonatal respiratory distress.

Classified	Simple model			Adjusted model		
	Distress (NRD ⁺)	No distress (NRD ⁻)	Total	Distress (NDR ⁺)	No distress (NRD ⁻)	Total
+	11	5	16	10	3	13
-	5	11	16	3	12	15
Total	16	16	32	13	15	28*

*missing data for malformation type

Figure S1. Distribution of CVR max values between infants born at term and infants born preterm






Figure S2. ROC curve for full-term (A, B) and preterm (C, D) infants, according to CVR max. Simple (A, C) and adjusted (B, D) models are presented. The area under the ROC (AUROC) values presented are means \pm SEM (95%CI)

A




AUROC before bootstrapping: 0.705 ± 0.044 (0.618 ; 0.790)
 AUROC after bootstrapping: 0.705 ± 0.045 (0.618 ; 0.791)

B




AUROC before bootstrapping: 0.717 ± 0.044 (0.631 ; 0.803)
 AUROC after bootstrapping: 0.711 ± 0.045 (0.623 ; 0.799)

C



AUROC before bootstrapping: 0.727 ± 0.094 (0.543 ; 0.910)
 AUROC after bootstrapping: 0.727 ± 0.096 (0.538 ; 0.915)

D



AUROC before bootstrapping: 0.846 ± 0.075 (0.700 ; 0.993)
 AUROC after bootstrapping: 0.846 ± 0.076 (0.698 ; 0.994)